Arcutis to present data from topical roflumilast clinical program at EADV 2022 Congress.
Arcutis Biotherapeutics, Inc. will present 4 abstracts for its topical roflumilast program in seborrheic dermatitis and psoriasis at the 31st European Academy of Dermatology and Venerology (EADV) Congress in Milan, virtually and in-person. In these abstracts, new data, including safety, efficacy, and tolerability in treating sensitive areas will be announced.
The topical cream and foam formulations of roflumilast are being developed as a once-daily, nonsteroidal, topical treatment for several dermatologic conditions. The highly potent and selective phosphodiesterase-4 (PDE4) inhibitor is an intracellular enzyme that increases the production of pro-inflammatory mediators. Roflumilast cream 0.3% (ZORYVE) was approved by the US Food and Drug Administration (FDA) for the topical treatment of plaque psoriasis in patients 12 years of age and older.
The oral presentation of the phase 3 pivotal trial of roflumilast foam in seborrheic dermatitis includes:
The 2022 EADV Congress includes over 600 presenters and over 170 sessions.2